Solidion Technology Inc. (NASDAQ: STI) director Tjon Karin-Joyce bought 5,000 shares at $7.20 per share on 14 September 2026. The transaction represented about 8.6% of the resulting share holding.
DexCom (NASDAQ:DXCM) has helped transform how people with diabetes manage their condition, replacing painful finger-prick tests with small sensors that track glucose continuously. As that technology spreads to more people, glucose-monitoring adoption has become a crucial healthcare theme forNasdaq100 investors, with a large and …
CrowdStrike Holdings, Inc. (NASDAQ: CRWD) CEO Kurtz George sold 20,000 shares. Following the transactions, the filing reported that he owned 7,756,019 shares. The activity took place between 11 September 2026 and 14 September 2026.
Datadog, Inc. (NASDAQ: DDOG) Chief Revenue Officer Sean Michael Walters sold 11,710 shares in five transactions priced between $219.68 and $224.45 per share. The transactions were dated 11 September 2026.
GE HealthCare (NASDAQ:GEHC) makes the scanners that hospitals use to see inside the human body, and it is now adding artificial intelligence to make those machines smarter and more useful. As hospitals invest in imaging and adopt AI, GE HealthCare offersNasdaq100 investors aBusinessstory rooted …
Gilead Sciences (NASDAQ:GILD) owes its position to a single therapeutic area it has dominated for decades, HIV, and its future depends on defending that franchise while proving it can grow beyond it. ForNasdaq100 investors, the twin questions of how well its HIV business holds …
Guidewire Software, Inc. (NYSE: GWRE) Chief Financial Officer Cooper Jeffrey Elliott exercised 37,826 options at $0 per share on September 15, 2026. The filing reports his share ownership and derivative-securities position following the transaction.
● Gossamer Bio plans to submit an NDA for seralutinib in pulmonary arterial hypertension in September 2026, backed by Phase 3 PROSERA and Phase 2 TORREY data.
INNODATA INC. (NASDAQ: INOD) elected Admiral Michael S. Rogers as an independent director effective September 10, with annual compensation of $75,000. The package includes equal monthly payments and a prorated equity grant under Innodata’s amended equity compensation plan.
IDEXX Laboratories (NASDAQ:IDXX) has built a highly profitableBusinessout of a simple trend: people increasingly treat their pets as family and spend accordingly on their health. As the leader in veterinary diagnostics, IDEXX makes pet testing a distinctive and durable growth theme within theNasdaq100.